Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression

Cell Death Dis. 2023 Jun 29;14(6):383. doi: 10.1038/s41419-023-05892-z.

Abstract

Long non-coding RNAs (lncRNAs) are tissue-specific expression patterns and dysregulated in cancer. How they are regulated still needs to be determined. We aimed to investigate the functions of glioma-specific lncRNA LIMD1-AS1 activated by super-enhancer (SE) and identify the potential mechanisms. In this paper, we identified a SE-driven lncRNA, LIMD1-AS1, which is expressed at significantly higher levels in glioma than in normal brain tissue. High LIMD1-AS1 levels were significantly associated with a shorter survival time of glioma patients. LIMD1-AS1 overexpression significantly enhanced glioma cells proliferation, colony formation, migration, and invasion, whereas LIMD1-AS1 knockdown inhibited their proliferation, colony formation, migration, and invasion, and the xenograft tumor growth of glioma cells in vivo. Mechanically, inhibition of CDK7 significantly attenuates MED1 recruitment to the super-enhancer of LIMD1-AS1 and then decreases the expression of LIMD1-AS1. Most importantly, LIMD1-AS1 could directly bind to HSPA5, leading to the activation of interferon signaling. Our findings support the idea that CDK7 mediated-epigenetically activation of LIMD1-AS1 plays a crucial role in glioma progression and provides a promising therapeutic approach for patients with glioma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain
  • Cyclin-Dependent Kinases
  • Glioma* / genetics
  • Humans
  • Intracellular Signaling Peptides and Proteins / genetics
  • LIM Domain Proteins / genetics
  • RNA, Long Noncoding* / genetics
  • Regulatory Sequences, Nucleic Acid

Substances

  • Cyclin-Dependent Kinases
  • Intracellular Signaling Peptides and Proteins
  • LIM Domain Proteins
  • LIMD1 protein, human
  • RNA, Long Noncoding
  • CDK7 protein, human